Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer.

Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer Abbreviations (m)CRPC (metastatic) castration-resistant prostate cancer ePAD electronic Prostate Cancer Australian Database FDG fluorodeoxyglucose HSPC hormone-sensitive prostate cancer LN lymph nodes PET positron emission tomography PSMA prostate-specific membrane antigen WBBS whole-body bone scan Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-CT imaging has demonstrated greater sensitivity compared to conventional imaging modalities with CT and whole-body bone scan (WBBS) in the detection of metastatic prostate cancer [[1]]. A further 15 patients (17%) had dedicated CT alone in addition to PSMA PET-CT, while eight (9%) had additional WBBS alone in addition to PSMA PET-CT (Fig. [Extracted from the article]